By fusing enzyme fragments to antibodies, researchers from the Institute of Science Tokyo, in Japan, developed an innovative ...

Presented initial data from Phase 1b study suggesting GT-02287 has a disease-slowing effect consistent with the preclinical ...

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in ...

Patent covers brilaroxazine use for treating Pulmonary Fibrosis-Similar patents have also been granted in key markets around the world ...

Last year, researchers at the University of California, Riverside, developed a novel “molecular crowbar” strategy to degrade the oncogenic enzyme Pin1, a protein that is overexpressed in many tumors ...

Last year, researchers at the University of California, Riverside, developed a novel "molecular crowbar" strategy to degrade ...

GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related ...

New live-cell imaging data show that Telomir-1 markedly lowers intracellular iron levels at submicromolar concentrations in human keratinocytes, demonstrating potent cell penetration and iron-modulati ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

His decoding of the blueprint for life with Francis H.C. Crick made him one of the most important scientists of the 20th ...